Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Immix Biopharma, Inc.NASDAQ: IMMX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 38.29M shares rose 28.9% year over year, ahead of the +19.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +33.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.9% holds above the trailing-twelve-month pace of +19.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.29M+0.0% QoQ
Last fiscal yearDec 2025
32.97M+16.5% YoY
LTMMar 2026
34.62M+19.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.9%——
1 year+16.5%——
3-year CAGR+33.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
32.97M USD
Year-over-year change
+16.5%
4-year CAGR
+73.1%

Weighted Avg Shares (Diluted) vs competitors

How IMMX compares with its peers on the latest reported figures

  • IMMX's LTM Mar 2026 weighted avg shares (diluted) of 34.62M shares is the 10th highest of the 11 companies compared; the peer median is 72.27M shares.
  • Its year-over-year change of +19.9% is the 6th highest of 11, against a peer median of +20.6%.
  • Over three fiscal years its annual growth of +33.4% compares with a peer median of +17.2%.
IMMX Competitors Peer median
Weighted Avg Shares (Diluted) for IMMX and competitors
Company Period LTM YoY 3-year CAGR
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.2%+28.0%
IMMPImmutep LimitedFY2025145.58M +21.2%+19.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -11.6%-20.4%
ABVXAbivax S.A.FY202569.53M +10.3%+53.9%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding IMMX) 72.27M+20.6%+17.2%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000364.5K
Gross Profit0000(364.5K)
Gross Margin—————
Research & Development126.53K4.2M8.74M11.29M16.26M
Selling, General & Admin1.23M4.02M7.41M11.38M13.7M
Operating Expenses1.35M8.22M16.14M22.67M26.85M
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
EBITDA(24.2M)(8.22M)(15.56M)(21.54M)(29.04M)
EBITDA Margin—————
Operating Income(1.35M)(8.22M)(16.14M)(22.67M)(27.21M)
Operating Margin—————
Interest Income00572.01K1.02M555.53K
Interest Expense179.85K497000
Other Income / Expenses(23.03M)(497)572.01K1.02M(2.19M)
Income Before Tax(24.38M)(8.22M)(15.57M)(21.66M)(29.4M)
Pre-Tax Margin—————
Income Tax Expense6.01K10.27K26.42K41.04K37.72K
Net Income(24.38M)(8.23M)(15.43M)(21.61M)(29.44M)
Net Margin—————
EPS (Basic)(6.64)(0.59)(0.89)(0.76)(0.89)
EPS (Diluted)(6.64)(0.59)(0.89)(0.76)(0.89)
Weighted Avg Shares3.67M13.89M17.34M28.29M32.97M
Weighted Avg Shares (Diluted)3.67M13.89M17.34M28.29M32.97M

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.